PHSCNK-Modified and doxorubicin-loaded liposomes as a dual targeting system to integrin-overexpressing tumor neovasculature and tumor cells

References

• Allen TM, Brandeis E, Hansen CB, Kao GY, Zalipsky S. (1995). A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta, 1237: 99–108.
   PubMed Web of Science ®Google Scholar
• Crack JC, Green J, Le Brun NE, Thomson AJ. (2006). Detection of sulfide release from the oxygen-sensing [4Fe-4S] cluster of FNR. J Biol Chem, 281: 18909–18913.
   PubMed Web of Science ®Google Scholar
• Dijkgraaf I, Rijnders AY, Soede A, Dechesne AC, van Esse GW, Brouwer AJ, Corstens FH, Boerman OC, Rijkers DT, Liskamp RM. (2007). Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes. Org Biomol Chem, 5: 935–944.
   PubMed Web of Science ®Google Scholar
• Donate F, Parry GC, Shaked Y, Hensley H, Guan XJ, Beck I, Tel-Tsur Z, Plunkett ML, Manuia M, Shaw DE, Kerbel RS, Mazar AP. (2008). Pharmacology of the novel antiangiogenic PeptideATN-161(Ac-PHSCN-NH2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth. Clin Cancer Res, 14: 2317–2324.
   Google Scholar
• Folkman J. (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med, 285: 1182–1186.
   PubMed Web of Science ®Google Scholar
• Folkman J. (1990). What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst, 82: 4–6.
   PubMed Web of Science ®Google Scholar
• Harris JM, Yalpani M, Van A lstine JM, Struck EC, Case MG, Paley MS, Brooks DE. (1984). Synthesis and characterization of poly(ethylene glycol) derivatives. J Polym Sci: Polym Chem Edn, 22: 341–352.
   Web of Science ®Google Scholar
• Hood JD, Cheresh DA. (2002). Role of integrins in cell invasion and migration. Nat Rev Cancer, 2: 91–100.
   PubMed Web of Science ®Google Scholar
• Hynes RO. (1992). Integrins: versatility, modulation, and signaling in cell adhesion. Cell, 69: 11–25.
   PubMed Web of Science ®Google Scholar
• Ishida O, Maruyama K, Tanahashi H, Iwatsuru M, Sasaki K, Eriguchi M, Yanagie H. (2001). Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm Res, 18: 1042–1048.
   PubMed Web of Science ®Google Scholar
• Jaffe EA, Nachman RL, Becker CG, Minick CR. (1973). Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest, 52: 2745–2756.
   PubMed Web of Science ®Google Scholar
• Jere E, Meredith J, Martin AS. (1997). Integrins, adhesion and apoptosis. Trends Cell Biol, 7: 146–150.
   PubMed Web of Science ®Google Scholar
• Khalili P, Arakelian A, Chen G, Plunkett ML, Beck I, Parry GC, Doñate F, Shaw DE, Mazar AP, Rabbani SA. (2006). A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther, 5: 2271–2280.
   PubMed Web of Science ®Google Scholar
• Kim S, Bell K, Mousa SA, Varner JA. (2000). Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol, 156: 1345–1362.
   PubMed Web of Science ®Google Scholar
• Koning GA, Morselt HW, Velinova MJ, Donga J, Gorter A, Allen TM, Zalipsky S, Kamps JA, Scherphof GL. (1999). Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells. Biochim Biophys Acta, 1420: 153–167.
   PubMed Web of Science ®Google Scholar
• Livant DL, Brabec RK, Pienta KJ, Allen DL, Kurachi K, Markwart S, Upadhyaya A. (2000). Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Res, 60: 309–320.
   PubMed Web of Science ®Google Scholar
• Marty C, Schwendener RA. (2005). Cytotoxic tumor targeting with scFv antibody-modified liposomes. Methods Mol Med, 109: 389–402.
   PubMedGoogle Scholar
• Maruyama K, Takizawa T, Takahashi N, Tagawa T, Nagaike K, Iwatsuru M. (1997). Targeting efficiency of PEG–immunoliposome conjugated antibodies at PEG terminals. Adv Drug Del Rev, 24: 235–242.
   Web of Science ®Google Scholar
• Matsumura Y, Maeda H. (1986).A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res, 46: 6387–6392.
   PubMed Web of Science ®Google Scholar
• Muggia F. (1999). Doxorubicin–polymer conjugates: further demonstration of the concept of enhanced permeability and retention. Clin Cancer Res, 5: 7–8.
   PubMed Web of Science ®Google Scholar
• Neri D, Bicknell R. (2005). Tumour vascular targeting. Nat Rev Cancer, 5: 436–446.
   PubMed Web of Science ®Google Scholar
• Plunkett ML, Beck I, Avery J, Tel-Tsur Z, Yu M, Livant DL, Arimura J, Truong F, Mazar AP. (2003). Combining low dose chemotherapy with low dose anti-angiogenic agents (ATN-161 and ATN-224) leads to increased anti-tumor activity in prostate cancer xenograft models. Proc Am Assoc Cancer Res, 44: 3730.
   Google Scholar
• Varne JA, Cheresh DA, Cheresh DA. (1997). Integrins and cancer. Curr Opin Cell Biol, 8: 724–730.
   Web of Science ®Google Scholar
• Sapra P, Allen TM. (2003). Ligand-targeted liposomal anticancer drugs. Prog Lipid Res, 42: 439–462.
   PubMed Web of Science ®Google Scholar
• Serini G, Valdembri D, Bussolino F. (2006). Integrins and angiogenesis: a sticky business. Exp Cell Res, 312: 651–658.10.1016/j.yexcr.2005.10.020
   PubMed Web of Science ®Google Scholar
• Singh M, Ferdous AJ, Kanikkannan N, Faulkner G. (2001). Stealth monensin immunoliposomes as potentiator of immunotoxins in vitro. Eur J Pharm Biopharm, 52: 13–20.
   PubMed Web of Science ®Google Scholar
• Singh SR, Grossniklaus HE, Kang SJ, Edelhauser HF, Ambati BK, Kompella UB. (2009). Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther, 16: 645–659.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang X, Zhang Y, Yang S, Wang J, Zhang X, Zhang Q. (2009). RGD-modified polymeric micelles as potential carriers for targeted delivery to integrin-overexpressing tumor vasculature and tumor cells. J Drug Target, 17: 459–467.
   PubMed Web of Science ®Google Scholar
• Xiong XB, Huang Y, Lu WL, Zhang H, Zhang X, Zhang Q. (2005a). Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo. Pharm Res, 22: 933–939.
   PubMed Web of Science ®Google Scholar
• Xiong XB, Huang Y, Lu WL, Zhang X, Zhang H, Nagai T, Zhang Q. (2005b). Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Control Release, 107: 262–275.
   PubMed Web of Science ®Google Scholar
• Xiong XB, Huang Y, Lu WL, Zhang X, Zhang H, Nagai T, Zhang Q. (2005c). Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo. J Pharm Sci, 94: 1782–1793.
   PubMed Web of Science ®Google Scholar
• Zhao H, Wang JC, Sun QS, Luo CL, Zhang Q. (2009). RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer. J Drug Target, 17: 10–18.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Chen H, Liu XP, Jiang JH, Shen GL, Yu RQ. (2008). An ultrasensitive chemiluminescence immunosensor for PSA based on the enzyme encapsulated liposome. Talanta, 77: 809–814.
   Web of Science ®Google Scholar